Use of CCR3-Inhibitors
AssigneeAlkahest, Inc.
InventorsMichael Chadham Nivens, Thierry Bouyssou, Peter Seither, Rolf Goeggel
Life of this patent
Estimating the term…
Abstract
The present invention relates to CCR3 inhibitors of formula 1, wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2. for use as a medicament for the treatment of diseases selected from dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), nasal polyposis, eosinophilic esophagitis, eosinophillic gastroenteritis (e.g. eosinophilic gastritis and eosinophilic ententeritis), hypereosinophilic syndrome and Churg Strauss syndrome.
Claims21
1-11. (canceled)
A method of treating a patient with an eosinophilic inflammation disease condition, the method comprising:
- administering to a patient a therapeutically effective amount of a compound of formula 1
- wherein
- R1 is H, C1-6-alkyl, C1-6-haloalkyl;
- R2 is H, C1-6-alkyl;
- X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate;
- and
- j is 1 or 2.
A method of treating a patient with an eosinophilic inflammation disease condition, the method comprising:
- administering to a patient a therapeutically effective amount of a compound of formula 1
- wherein
- R1 is H, C1-6-alkyl, C1-6-haloalkyl;
- R2 is H, C1-6-alkyl;
- X is chloride;
- and
- j is 2.
Dependencies are inferred from the claim text.